DekaBank Deutsche Girozentrale boosted its stake in Amgen, Inc. (NASDAQ:AMGN) by 0.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 888,144 shares of the medical research company’s stock after buying an additional 4,565 shares during the quarter. Amgen makes up approximately 1.2% of DekaBank Deutsche Girozentrale’s portfolio, making the stock its 10th largest holding. DekaBank Deutsche Girozentrale owned approximately 0.12% of Amgen worth $152,472,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of AMGN. Baker Ellis Asset Management LLC purchased a new position in Amgen in the 3rd quarter valued at about $108,000. Jackson Grant Investment Advisers Inc. lifted its stake in Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after buying an additional 5 shares in the last quarter. Phocas Financial Corp. purchased a new position in Amgen in the 2nd quarter valued at about $110,000. Omnia Family Wealth LLC lifted its stake in Amgen by 25.3% in the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock valued at $125,000 after buying an additional 147 shares in the last quarter. Finally, Grove Bank & Trust lifted its stake in Amgen by 87.4% in the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock valued at $126,000 after buying an additional 341 shares in the last quarter. 78.48% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amgen, Inc. (NASDAQ AMGN) opened at $185.54 on Wednesday. The stock has a market cap of $134,690.00, a P/E ratio of 16.76, a PEG ratio of 2.70 and a beta of 1.36. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. Amgen, Inc. has a 1-year low of $150.38 and a 1-year high of $191.10.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.85%. This is an increase from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio (DPR) is currently 41.55%.
Amgen declared that its board has authorized a share buyback program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.
A number of research analysts recently weighed in on the stock. Oppenheimer set a $205.00 price target on shares of Amgen and gave the company a “buy” rating in a research note on Friday, January 5th. Vetr lowered shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 price target on the stock. in a research note on Wednesday, January 3rd. Piper Jaffray Companies reiterated a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. Mizuho set a $192.00 price objective on shares of Amgen and gave the company a “buy” rating in a report on Thursday, December 28th. Finally, Citigroup downgraded shares of Amgen to a “neutral” rating in a report on Monday, December 18th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $190.15.
In other news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total transaction of $269,665.75. Following the completion of the sale, the executive vice president now owns 56,106 shares in the company, valued at approximately $9,921,223.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders have sold a total of 7,050 shares of company stock valued at $1,225,765 in the last 90 days. Insiders own 0.19% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.